NEW YORK, April 24, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and BrightFocus Foundation today announced a funding collaboration that will support a Phase I human clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer's disease. Through this partnership, the organizations are working to address a gap in funding that exists for these types of early stage studies. The trial will be conducted by ReXceptor Inc., a biotechnology company set-up by researchers at Case Western Reserve University (CWRU), and will examine the efficacy of bexarotene on key Alzheimer's disease indicators, including brain amyloid beta and apolipoprotein E (apoE).
"This clinical trial will evaluate if bexarotene can affect critical biomarkers in the human brain, a key step in the quest to develop effective and safe treatments for Alzheimer's patients," said Howard Fillit , MD, executive director and chief scientific officer of the Alzheimer's Drug Discovery Foundation. "We are grateful to BrightFocus Foundation for partnering with us to fund this important study."
Bexarotene has been commercially available in the US for more than a decade as an orally administered treatment for T-cell lymphoma. Recently, Gary Landreth , PhD, the Riuko and Archie G. Co Professor of Neurosciences and Director of the Alzheimer's Research Laboratory at CWRU's School of Medicine, along with other researchers, demonstrated that bexarotene might also be useful in the treatment of Alzheimer's disease. Landreth's group showed that bexarotene increased brain apoE protein levels and cleared amyloid from the brain (a key target for Alzheimer's disease) of mice genetically engineered to exhibit some of the characteristics of Alzheimer's disease, which resulted in improved me
|SOURCE Alzheimer's Drug Discovery Foundation|
Copyright©2012 PR Newswire.
All rights reserved